CytoDyn’s Chief Medical Officer Dr. Scott Kelly to Present at Triple Negative Breast Cancer Drug…
VANCOUVER, Wash., April 27, 2021 (GLOBE NEWSWIRE) - CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Firm"), a late-stage biotechnology firm creating Leronlimab (Vyrologix or PRO 140), a CCR5 antagonist with potential for a number of…